Table 1.
Characteristics of evaluable case patients with cytomegalovirus (CMV) retinitis (CMVR) diagnosed during follow-up and control subjects who did not develop CMVR during follow-up.
| Factor | Case patients (n = 11) |
Control subjects (n = 12) |
|
|---|---|---|---|
| Age, median years (range) | 42 (35–52) | 42 (33–59) | |
| Percentage of men | 91 | 67 | |
| Race, percentage of subjects | |||
| White | 73 | 67 | |
| Black | 27 | 8 | |
| Hispanic | 0 | 25 | |
| Time from AIDS diagnosis to LSOCA entry, median years (range) | 5.6 (1.6–12) | 4.9 (0.2–11.7) | |
| Plasma HIV RNA, median log copies/mL (range)a | 5.534 (1.699–6.000) | 4.891 (1.491–5.875) | |
| No. of subjects with detectable plasma CMV DNA level/total no. of subjectsa | 3/11 | 1/8 | |
| Hemoglobin level, median g/dLa | 12.4 | 12.9 | |
| Absolute T cell count, median cells/mL (range) | |||
| CD4+ T cell count at entry | 13 (0–351) | 12 (2–349) | |
| CD4+ T cell count on date that the PBMC specimen was obtained | 16 (2–336) | 44 (2–830) | |
| CD8+ T cell count on date that the PBMC specimen was obtained | 366 (62–890) | 491 (163–1584) | |
NOTE. LSOCA, Longitudinal Studies of the Ocular Complications of AIDS.
a
On date that the PBMC specimen was obtained (2–6 months before CMVR diagnosis in case patients).